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In the Editorial launching the very first issue of The Journal of
Investigative Dermatology, Dr. Marion Sulzberger wrote, ‘‘y the
laboratory investigation of today is the practice of tomorrow’’ [1]. This
50th Anniversary Issue is filled with evidence of the maturation of
investigative dermatology, but what has been the impact of such basic
research in cutaneous biology on the practice of dermatology? The
purpose of this treatise is twofold: (1) To examine the state of research in
cutaneous biology in 1988 by presenting how the modern tools of
molecular and cellular biology are being applied to the study of the skin,
and (2) to demonstrate how this scientific foundation has provided the
basis for modern therapeutics. In 1988, the investigators involved in
research in cutaneous biology brought a wide range of training and
different experimental approaches to their areas of investigation: the
molecular biologist analyzing the subcellular details of keratinocyte
differentiation, of collagen synthesis, or of the synthesis and secretion of
the extracellular matrix; the cell biologist studying signal transduction or
membrane function; the cellular immunologist dissecting the complex
interactions of the immune response in the skin; the experimental
pathologist studying wound healing; the photobiologist evaluating the
subcellular, cellular and systemic effects of ultraviolet light; the
biochemist studying melanization or the barrier function of lipids of the
stratum corneum; the radiation biologist characterizing DNA repair
mechanisms; the pharmacologist measuring percutaneous absorption;
the physiologist considering the physical properties of the skin; the cell
biologist or pharmacologist studying the mechanism of action of drugs.
The historical term ‘‘investigative dermatology’’ has surely evolved to
include all aspects of cutaneous biology. The modern scientist studying
the biology of the skin may be in a Department of Dermatology or other
clinical departments such as Surgery, Medicine or Pediatrics, or in such
basic science departments of Molecular, Cellular and Developmental
Biology, Anatomy, Pathology, Microbiology/Immunology, or Pharmaco-
logy. Although this broad spectrum of investigation is published in many
journals, The Journal of Investigative Dermatology is the one place where
work on all aspects of cutaneous biology is welcomed. It is the major
journal which encompasses the complete spectrum of research in
cutaneous biology. This treatise will present a selected summary of the
state of research in cutaneous biology in the 50th Anniversary year of the
founding of the SID and JID, and also a perspective on the influence of
research in cutaneous biology on the practice of dermatology. The first
section will demonstrate how the tools of molecular and cellular biology
are being applied in 1988 to study the complex structure and function of
the skin. Representative papers from the JID and other journals during
the 50th Anniversary year will be used as examples. The second section
will demonstrate how this basic knowledge has influenced treatment of
disease.
THE CURRENT STATE OF RESEARCH IN
CUTANEOUS BIOLOGY
Sophisticated techniques of laboratory research have permitted investi-
gators to study in detail the molecules which are the building blocks of
cells, and to learn how these molecules control cellular functions. The
tools of molecular biology can be used to better understand the
molecular details of gene activation and transcription and of protein
synthesis, and have led to cloning and sequencing of the genes and to
determination of structure of certain proteins. This research has provided
probes to facilitate analysis of protein glycosylation, packaging and
secretion, and to study hormones, receptors, growth factors, cytokines,
matrix proteins, cytoskeletal and membrane components. Understanding
interactions at the molecular and cellular levels leads to better under-
standing of complex cellular interactions. The complicated interaction of
cytokines, growth factors, adhesion molecules, and recognition structures
in the immune system is an excellent example of complex cellular
interactions. Such complexity also is found in the chemistry of nerve
conduction, in the interactions of the dermis and epidermis producing
the basement membrane zone, in the biology of the adnexal structures of
the skin, and in the interactions of endothelial cells, mast cells, and
fibroblasts in controlling cutaneous microcirculation. Finally, the sum of
such complex interactions comprises the biology of each organ system,
and the equally complex interactions among organ systems define the
biology of the whole organism. The tools of molecular biology enhance
research tremendously at all levels of complexity in this hierarchy, from
the molecular to organ system level (Fig 1).
Molecular Biology: An Important Tool to Study Normal
Pathology and Mechanisms of Disease
The goals of molecular biology are to identify the DNA and RNA nucleo-
tide sequences which code for particular protein amino acid sequences,
and to determine how these proteins unfold and are organized into
functional units. The basic tools of molecular biology include: restriction
enzymes, which cut DNA at specific, defined nucleotide sites; ligase
enzymes, which join DNA fragments, producing recombinant molecules;
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and the enzyme reverse transcriptase, which produces DNA (comple-
mentary DNA or cDNA) from RNA sequences and facilitates the
sequencing of genes coding for particular proteins. The sequencing of
genes and determination of protein primary, secondary and tertiary
structure are important investigative goals, but this research may also
provide clues to the control of gene expression.
Molecular Probes to Study Complex Biology. Molecular biology
techniques can also expand our understanding of how particular genes,
through their protein products, affect cell function, complex cellular
interactions, and the pathophysiology of disease. Molecular biology
provides a variety of highly specific and useful probes for studying genes,
message and protein structure and distribution as summarized in Table I.
These tools are being applied with impressive effectiveness in dissecting
the complexities of cutaneous biology from the molecular to the organ
level. A subsequent section of this paper will summarize how these
tools have been applied in 1988 to study several important groups of
proteins central to cutaneous biology: growth factors, extracellular
matrix proteins, immunologic cytokines, and antigens recognized in
autoimmune skin diseases, adhesion molecules, and keratins.
Restriction Fragment Length Polymorphisms. A very important tool
in molecular genetics is the analysis of restriction fragment length
polymorphisms (RFLP) to determine genetic alleles which are closely
linked with particular diseases. Restriction enzymes are used to cut DNA
at specific sites determined by nucleotide sequence. The resulting
fragments are then separated on a gel by molecular weight and are probed
for the gene of interest. As shown in Figure 2, DNA sequences with different
restriction sites produce fragments of different length. The different patterns
from different individuals represent polymorphisms in nucleotide sequence.
These polymorphisms can be compared in different diseases and control
groups and then analyzed to determine if the gene in question contains
alleles which are highly associated with particular diseases.
In 1988, analysis of RFLPs has produced important information on the
genetic control of two dermatologic diseases, pemphigus vulgaris and
psoriasis vulgaris. Two recent papers report the detection of disease-
specific RFLPs in one genetic subset of pemphigus vulgaris, a finding
tantamount to identifying an allele of the HLA Dq-beta gene which
determines the occurrence of disease [2,3]. The allele in question was
invariably present in all pemphigus patients and was present in few of the
controls. In the past, close linkage of pemphigus vulgaris with particular
HLA alleles has been viewed as evidence of the genetic determination of
the immunologic reactivity that leads to the disease. This new work
identifies one allele in the HLA D region which may determine disease.
Psoriasis is a heterogeneous disease of complex pathophysiology.
Ozawa and his coworkers [4] analyzed RFLPs of genomic DNA of the
HLA-C gene in HLA-Cw6 and Cw7-positive psoriatic patients and
controls. No polymorphisms were seen in the psoriatic patients, and two
fragments uniformly found in psoriatics were lacking in some controls.
Although this work does not identify the gene responsible for psoriasis, it
indicates that certain invariant alleles in the HLA-C locus may be
necessary for the development of disease in one subset of psoriasis. Thus,
Figure 1. Hierarchy of Structure and Function.
Table I. Probes Developed Through Application of
Molecular Biology
1. DNA probes to identify particular DNA sequences in Southern blot
analysis and mRNA in Northern blot analysis.
2. cDNA probes to identify specific cellular mRNA by hybridization in situ.
3. Specific RNA probes to identify specific genes in cell nuclei by
hybridization in situ.
4. Short nucleotide probes to identify particular segments in genes in
nuclei or on Southern blots.
5. Short nucleotide primers to amplify particular genes by the
polymerase chain reaction (PCR).
6. Production of large amounts of recombinant molecules, facilitating
more detailed study of protein function.
7. Use of recombinant molecules to produce highly specific monoclonal
antibody probes to different protein epitopes.
Figure 2. Restriction Fragment Length Polymorphisms (RFLPs). Arrows
indicate the restriction site for the enzyme BamHI. In B circle indicates a
different nucleotide sequence. When the different fragments are analyzed by
Southern analysis using a labelled probe for a segment of this DNA, fragments
of different size are identified from the two individuals. From Ozawa et al.,
J Invest Dermatol, 90:402–405, 1988.
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in two major skin diseases suspected to be genetically determined, there
are now techniques which can identify the genes which determine
disease.
Study of Gene Rearrangement. An important discovery in molecular
genetics was that certain specialized cells randomly rearrange their genes
during certain stages of differentiation or activation [5,6]. This is an
important means of generating diversity in gene products. Such gene
rearrangement in the course of B lymphocyte and T lymphocyte
activation leads to the vast repertory of different antibody and T cell
receptor specificities. Study of this phenomenon has led to basic and
critical information regarding the control of the specificity of the immune
response.
Such gene rearrangements have also been studied as markers of
clonality to better understand the biology of B and T cell lymphomas [7].
In investigative dermatology, the study of T cell receptor gene rearrange-
ments in cutaneous T cell lymphoma (CTCL) has been effectively used
to understand the origin of clonal disease in this indolent lymphoma [8]. In
a current JID paper, Berger and coworkers [9] extend previous
observations on clonality in CTCL by demonstrating dual genotypes in a
number of CTCL patients. In addition to clonal rearrangement of the beta
chain gene of the T cell receptor in 13 patients, immunoglobulin gene
rearrangements were found in four patients. The precise meaning of gene
rearrangements in T cell lymphomas is not totally clear due to the
apparent demonstration of clonality in the benign disease lymphomatoid
papulosis [10]. These types of study should allow us to better understand
patterns of T cell activation and the mechanisms of malignant
transformation.
Understanding Mechanisms for Control of Gene Transcription
and Translation. Understanding how the promotion of particular genes
occurs, how exons are regulated, and how transacting factors control
gene expression are important questions in molecular biology. Two
papers in the JID illustrate how such questions are being addressed in the
study of keratin and elastin synthesis. The coordinate synthesis of keratins
at different stages of differentiation is an important aspect of epidermal
differentiation. Lessin et al. [11] studied the control of synthesis of Keratin
1 (Type II 67 kDa) and Keratin 10 (Type I 57 kDa) which are co-expressed
in terminally differentiated epidermal cells. They mapped these two
genes to chromosomes 12 and 17, respectively. Since they are not linked
on the chromosome, but are co-expressed during differentiation, it is
reasonable to postulate that transacting factors regulate their transcription
and translation.
How is diversity in elastin molecules determined? To study this
question, Fazio et al. [12] constructed a cDNA library from fibroblast
mRNA and screened by plaque hybridization with elastin cDNAs. They
found in the recombinant plaques identified that there was considerable
variability in the primary nucleotide sequence of the elastin cDNAs. The
authors felt that alternative splicing of exons from the primary elastin
transcripts produced the variability, and proposed that this might be an
important means of producing elastin with variable biologic properties.
Localization of the Site of Protein Synthesis by In Situ
Hybridization. As detailed earlier, molecular probes may complement
previous studies of protein localization tissue by demonstrating the genes
or RNA message coding for proteins and by indicating which cells
encode for a protein. Again, two recent JID papers demonstrate the
power of in situ hybridization techniques. The production of fibronectin
by basal cell epitheliomas (BCE) and its presence around tumor islands
has been demonstrated in numerous elegant lmmunohistology studies.
Peltonen et al. [13] recently confirmed that the tumor cells in a BCE
contain mRNA for fibronectin and secrete the protein product. Figure 3
shows fibronectin-specific mRNAs in the peripheral pallisading basal
cells in a BCE.
The production of fibrosis in scleroderma is a complex process in
which immunologic factors, mast cells, and growth factors all appear to
contribute. Using cDNA probes for pro 1(1) and pro 1 (III) collagen,
Kahari et al. [14] showed increased levels of messenger RNA for
procollagen in fibroblasts associated with inflammatory cells in the
dermis of scleroderma lesions. As shown in Figure 4, the pro-
collagen message appears associated with blood vessels and inflam-
matory cells. This evidence strongly implicates the interaction of
inflammatory cells (and perhaps mast cells) and endothelial celis in the
local activation of collagen synthesis by transcription of procollagen
message.
Examples of Application of Advances in Molecular and Cellular
Biology to the Understanding of Cutaneous Biology and Disease
Although it is impossible to consider here all areas of research in cutaneous
biology in which modern molecular biology has produced significant
advances, we will discuss progress relating to six major groups of crucial
proteins which are centrally involved in many cutaneous diseases: growth
factors, extracellular matrix proteins, immunologic cytokines, antigens
recognized in autoimmune diseases, adhesion molecules, and intermedi-
ate filaments. Understanding of the roles of these proteins has been greatly
expanded by recent advances in molecular biology.
Growth Factors. The major growth factors with implications for
cutaneous biology are listed in Table II. For most of these factors,
the genes have been sequenced, protein sequences and structures
have been determined, and recombinant molecules have been devel-
oped. In addition, cellular receptors for the factors have been identified
and are being characterized. With the elegant probes for growth
factors and for their receptors that have been developed, extensive
studies of the function and relevance of these factors to skin biology and
disease are underway. It is impressive to realize that all of this effort
has evolved from the simple observations by Stanley Cohen and his
colleagues, featured as a ‘‘Citation Classic’’ in another section of this
issue (pages).
There are many current papers describing important functions of
growth factors in the skin. Two examples are papers by O’Keefe et al.
[15], demonstrating the stimulation of the growth of keratinocytes in vitro
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Figure 3. Spatial distribution of fibronectin m-RNAs in a basal cell
epithelioma (Panel C) as detected by in situ hybridization with human
fibronectin specific cDNA. Large arrows indicate peripheral basal cells
with many grains. Grains also are seen in some dermal nbroblasts (small
arrows) and also in cells within the epithelial islands (asterisk). From
Peltonen et al., J Invest Dermatol, 91:289–293, 1988.
by basic fibroblast growth factor (bFGF), and Halaban et al. [16],
showing similar growth stimulation of melanocytes by bFGF. Perhaps
bFGF is an important autocrine factor controlling keratinocyte prolifera-
tion and differentiation, and modulating melanocyte proliferation
and response to biological stimuli such as ultraviolet light (UVL) and
vitamin D.
A particularly important contemporary paper is the report by Ellis
et al. [17] studying the implication of growth factors in paraneoplastic
syndromes. These Vanderbilt University investigators described a patient
with melanoma who also had acanthosis nigricans, extensive seborrheic
keratoses, and acrochordons. Based on the knowledge that epidermal
growth factor (EGF) receptors bind both EGF and transforming growth
factor alpha (alpha-TGF), and that this ligand-receptor interaction
appears to be important in controlling the growth of epidermal
keratinocytes, they studied the expression of EGF receptors, the binding
of EGF and alpha TGF in tissue, and the excretion of growth factors
in the urine. This patient exhibited elevated EGF receptors in the skin
and elevated alpha-TGF in the urine. After removal of the tumor, the
acanthosis nigricans, seborrheic keratoses and acrochordons regressed,
the tissue EGF receptors decreased, and the urine alpha-TGF decreased.
The implication of this study is that growth factors may control the
epidermal hyperproliferation in certain cutaneous signs associated with
cancer. This study highlights the potentially important clinical roles of
such growth factors.
Extracellular Matrix Proteins. The maturation of research on the
extracellular matrix and its role in cutaneous biology is elegantly
summarized in this volume by Uitto, Olsen and Fazio. The cell biology
of newer collagens and matrix proteins is also detailed in recent
reviews in the Annual Review of Cell Biology [18,19]. As indicated in
Table III, a growing number of collagens, elastins, proteoglycans, and
matrix proteins have been found to be involved in basement membrane
assembly, dermal structure, and the interactions between dermis,
epidermis and epithelial cells.
In recent years, much emphasis has been placed on the role of
epidermal keratinocytes in the synthesis of basement membrane zone
components. Two 1988 JID papers illustrate that dermal fibroblasts may
also be involved in basement membrane formation. Woodley et al.
established that fibroblasts synthesize laminin [20], a crucial basement
membrane component also produced by keratinocytes. In a very
interesting study, Delvoye et al. [21] explored the role of fibroblasts on
basement membrane synthesis by using a complex composite culture
system. These investigators showed that the pattern of laminin, Type IV
collagen, and heparan sulfate proteoglycan produced by cultured
keratinocytes could be influenced by co-culture with fibroblasts, and
thereby established that fibroblasts influence the pattern of synthesis or
deposition of ECM components by keratinocytes.
New relationships of keratinocytes and the ECM are also being
appreciated. Enenstein and Furcht [22] reported that the neuronal
adhesion molecule epinectin could be synthesized by epidermal
keratinocytes and probably attaches to heparan sulfate proteoglycan,
thus establishing another potential adhesion mechanism between the
epidermis and the ECM. Another adhesion factor is thrombo-spondin,
which was shown by Varani and Nickoloff to be synthesized by cultured
human keratinocytes under conditions producing a basal cell phenotype.
Figure 4. The variability in pro 1(1) collagen mRNA levels in individual
fibroblasts from scleroderma skin is shown. Skin from an intermediate
stage scleroderma patient was hybridized with 35S-labeled cDNA probe
for pro 1(1) collagen and processed for autoradiography. Panel A shows
the photomicrograph and B the corresponding dark field image.
The bar represents 100mm. From Kahari et al., J Invest Dermatol,
90:664–670, 1988.
Table II. Growth Factors
Epidermal Growth Factor (EGF)
Transforming Growth Factor (TGF)
TGF-alpha
TGF-beta
Basic Fibroblast Growth Factor (bFGF)
Platelet-Derived Growth factor (PDGF)
Insulin-like Growth Factor (ILGF)
Myeloid Growth Factors
Multi-Colony stimulating factor (IL-3)
Granulocyte/macrophage-Colony stimulating factor (GM-CSF)
Macrophage-Colony stimulating factor (M-CSF)
Granulocyte-Colony stimulating factor (G-CSF)
Table III. Extracellular Matrix Proteins
Collagen Types I, II, III, IV, V, VI, VII
Elastin
Microfibrillar component
Fibrillin
Heparan Sulfate Proteoglycan
Proteoglycans/GAGs
Laminin
Fibronectin
Bullous Pemphigoid antigen
EBA antigen
Nidogen/entactin
Epinectin
Thrombospondin
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Culture conditions which favored differentiation terminated thrombo-
spondin synthesis [23]. Although gamma interferon decreased thrombo-
spondin synthesis, the transforming growth factors did not [24].
New relationships between ECM synthesis, growth factors, and
keratinocyte spreading are also being discovered. Transforming growth
factor beta (TGF-B) has been shown to be important in keratinocyte
spreading, and in secretion of proteins and enzymes involved in wound
healing. Hebda [25] described enhanced outgrowth of epidermal explant
cultures by TGF-B [Fig 5]. Mansbridge et al. showed that TGF-B enhances
the ‘‘regenerative maturation’’ of cultured keratinocytes, as indicated by
the patterns of proteins detected in gel electrophoresis [26]. Wikner et al
showed that TGF-B stimulates fibronectin synthesis and secretion by
cultured human keratinocytes (Fig 6); plasminogen activator synthesis
was also increased [27]. As previously reported, fibronectin [28] and
urokinase- and tissue-type plasminogen activator [29] are found in the
migrating epidermal tongue during wound healing in vivo. These studies
are relevant not only to the healing surgical wound, but also to repair of
epidermal and dermal injuries in inflammatory skin diseases, and to
development and repair in mechanobullous disorders.
Immunohgic Cytokines. For years, the complex cellular interactions
of the immune response have been poorly characterized. In many ways,
these interactions were ‘‘phenomenological’’; even the many lympho-
kines which modulate functions of different cells involved in inflamma-
tion were named by their function and not by their structure. Molecular
approaches to understanding the lymphokines have led to identification
of a basic core of important cytokines, listed in Table IV. Numerous
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Figure 5. Outgrowth of epidermis in porcine explant cultures after two days, culture in (a) 1% Fetal Bovine Serum or (b) 1% fetal Bovine Serum supplemented
with 1 ng/ml TGF-beta. Figures are labelled to show the explant (E) and the epidermal outgrowth (O). From Hebda PA, J Invest Dermatol, 91:440–445, 1988.
Figure 6. Immunofluorescent staining of the extensive deposition of
fibronectin in the extracellular matrix following tion in vitro with TGF-beta.
Straight arrows point to sites of cytoplasmic staining for fibronectin and
curved arrows point to extracellular staining for fibronectin. The bar
represents 50 microns. From Wikner et al. J Invest Dermatol,
91:207–212,1988.
Table IV. Immunologic Cytokines
Interleukins (IL-)
IL-1 alpha and beta
IL-2
IL-3
IL-4
IL-5
IL-6
Interferons
IFN-alpha
IFN-beta
IFN-gamma
Myeloid growth factors
GM-CSF
M-CSF
G-CSF
Tumor necosis facor (TNF)
TNF-alpha (cachectin)
TNF-beta (lymphotoxin)
previously identified lymphokine activities have been found to be
properties of a single protein. Sequencing the genes and proteins,
preparation of recombinant molecules, and development of antibody
probes to the proteins have eliminated many of the redundancies in
lymphokine nomenclature, and have facilitated detailed functional
analyses of the roles of cytokines in controlling the immune response.
Three of these cytokines are central in control of the immune response:
Interleukin 1 establishes the level of T cell responsiveness in any organ
and also has multiple systemic effects; Interleukin 2 activates primed
T lymphocytes and is required for T and B lymphocyte activation; and
gamma interferon has many important effects in amplifying the effector
arms of the immune response (for reviews, see [30,31]). The availability
of pure recombinant molecules and specific neutralizing antibodies will
facilitate investigation of the exact functional role of immunologic
cytokines.
The first immunologic cytokine found to be associated with the
epidermis was Epidermal Cell-Derived Thymocyte Activating Factor
(ETAF) [32,33], which has recently been shown to be largely IL-1, plus
IL-3 and IL-6 [30]. There was much active investigation in 1988 on
control of the secretion of IL-1 by different epidermal cells, and the
production of IL-1 inhibitors, especially contra IL-1, which is induced by
UV radiation [34]. An important development was the identification of
GM-CSF (a major colony stimulating factor for macrophages and
granulocytes) as a product of epidermal keratinocytes [35]. Not only is
this cytokine important in stimulating the proliferation of granulocytes
and macrophages (and possibly also Langerhans cells), but it is also an
important activator of granulocytes. As reported by Kapp and colleagues
[36], GM-CSF activates neutrophil oxidative metabolism. GM-CSF
released by epidermis is likely to be an important mediator of neutrophil
activation in the skin (Fig 7).
Our perception of the epidermis as an immunologic organ has
changed greatly over the past ten years. Perspectives on the importance
of Langerhans cells and Dendritic Epidermal T cells are provided
elsewhere in this issue, in the contribution by Krueger and Stingl
(pp 32S–52S) and in the Citation Classic by Soter (pp 161S–163S). The
production of cytokines, colony stimulating factors and growth factors by
epidermal keratinocytes also are crucial in the immunologic functions of
skin (for review of epidermal immunology, see [30]). As summarized in
Figure 8, the epidermis secretes cytokines which modulate T and B cell
activation and which regulate monocyte/macrophage as well as
granulocyte function. The epidermis also produces growth factors which
profoundly affect the function of fibroblasts, endothelial cells, and
keratinocytes and melanocytes, in addition to inflammatory cells. There
is still much to be learned about the complex interaction of cytokines and
growth factors in control of cutaneous immunologic responses, and such
insights are crucial to understanding the inflammatory dermatoses.
Antigens Involved in Autoimmune Diseases. Research in the
pathomechanisms of the bullous diseases has greatly enhanced our
understanding of the mechanisms of the variants of pemphigus, bullous
pemphigoid, dermatitis herpetiformis, herpes gestationis, and linear IgA
dermatosis. In most instances, distinctive autoantibodies and their tissue
localizations have been identified. This knowledge has revolutionized
the diagnosis of the immunologic bullous diseases and has provided
a solid basis for considering and developing new treatments.
Another important aspect of this research is the use of antibody
probes from patients’ sera to characterize antigens which are biologically
important components of the epidermis, basement membrane zone and
dermis. Several important papers in this area can be found in the 1988
literature. In a landmark paper, Eyre and Stanley report that pemphigus
vulgaris (PV) and pemphigus foliaceus (PF) can be absolutely distin-
guished on a molecular level [37]. Pemphigus vulgaris sera immunopre-
cipitate a complex of polypeptides of 210,130 and 85 kDa, while
pemphigus foliaceus sera immunoprecipitate a complex of 260,160,110
and 85 kD. The 85 kD protein is common to both complexes. The authors
speculate that these complexes are involved in keratinocyte adhesion.
Epidermolysis bullosa acquisita (EBA) patients’ sera contains an
autoantibody which reacts with 145 and 290 kDa proteins in skin. Two
papers fromWoodley and his colleagues in 1988 further characterize this
antigen [38,39]. The 145 protein appears to arise from the 290 kDa
protein by collagenase digestion. EBA sera recognize the carboxy-
terminus of type VII procollagen extracts in skin, as well as purified type
VII procollagen. The collagenous domain of the EBA antigen is located in
the sub-lamina densa region, and is likely to be a part of the type VII
collagen found in the anchoring filaments.
Stanley and colleagues [40] have also apparently identified the major
bullous pemphigoid antigen as a 230 kD polypeptide which is best
identified by immunoprecipitation of extracts of cultured human
Figure 7. Stimulation of polymorphonuclear leukocyte oxidative metabolism
by GM-CSF. From Kapp A. et al., J Invest Dermatol, 91:49–55, 1988.
Ultrastructural detection of granulocyte activation induced by recombinant
human GM-CSF. A, Nonstimulated PMN, 30min/37 1C, SEM; B, Non-
stimulated PMN, 30min/37 1C, TEM; C, PMN stimulated with recombinant
human GM-CSF (103 U/ml), 30min/37 1C, SEM;D, PMN stimulated with
recombinant human GM-CSF (10U/ml), 30min/37 1C, TEM; E, PMN
stimulated with PMA (10 ng/ml), 15min/37 1C, SEM; F, PMN stimulated with
PMA (10ng/ml), 15min/37 1C, TEM; G, Ultrastructural detection of hydrogen-
peroxide production following stimulation of PMN with recombinant human
GM-CSF (103 U/ml), 30min/37 1C, TEM; and H, Ultrastructural detection of
hydrogen-peroxide production following stimulation of PMN with PMA
(10ng/ml), 15min/37 1C, TEM.
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keratinocytes, and less well by immunoblotting of extracts of human
epidermis. Other immunoreactive bands can be identified using BP
patients’ sera, but the authors believe that this is the major BP antigen.
Herpes gestationis (HG) is an interesting disease occurring during
pregnancy which has many similarities to bullous pemphigoid, prompt-
ing the use of the term ‘‘pemphigoid gestationis’’ by some researchers to
describe HG. Using the sera of 16 HG patients, Morrison et al. [41] found
IgG antibodies which bound to a 180 kD protein in 89% of the cases. In
contrasting this to BP, they also found that 71% of BP sera contained IgG
antibodies which bound to a 1240 kDa band, but that 47% also bound to
a 180 kDa protein which co-migrated with the HG protein. The authors
conclude that this is strong evidence for immunologic cross-reactivity
between HG and BP.
Adhesion Molecules. We have already considered the interrelation-
ships of immunologic cytokines and growth factors in the activation and
control of the immune response. Another area of immunology in which
molecular biology has produced an explosive growth of new information
is the characterization of the proteins which mediate cell/cell interactions
involved in lymphocyte activation and control, and in generation of
factors which mediate specific recognition. Figure 9 shows many of the
components of the immunoglobulin gene superfamily [42], a large group
of peptides with strong sequence homology with immunoglobulins. The
lower panel contains proteins involved in the control of T cell interaction
with other cells and specific recognition: the T cell receptor (TCR)
composed of alpha and beta chains plus the gamma, delta and epsilon
components of CD3; CD1 (present on Langerhans cells); CD8 (present on
T cytotoxic/suppressor lymphocytes); CD4 (T helper lymphocytes); and
CD2 (adhesion molecule which is a receptor for LFA-3). The upper panel
shows homologous molecules on other cells: FcR (the Fc-Receptor, a
crucial component of recognition of antibody binding to antigen on a
cellular target); PDGFR and CSF-1R (receptors for growth factors platelet
derived growth factor and Colony Stimulating Factor 1); and N-CAM
(a neural adhesion molecule). Cloning the genes for these proteins has
been crucial in developing the tools to understand better the complex
interactive biology of the immune response and inflammation. The
interaction of specific recognition structures and antigens, adhesion
molecules and their ligands, and growth factors or cytokines and their
receptors are all crucial in the regulation of the immune response.
Another homologous member of the Immunoglobulin Super-gene
family [43] is the Intercellular Adhesion Molecule 1 (ICAM-1), an
adhesion molecule with important implications for cutaneous cells
involved in inflammation and wound repair and differentiation. The
interaction with the ligand and its receptor LFA-1 provides an important
bridge between the Immunoglobulin super-family and the Integrin
superfamily of cellular adhesion receptors [44,45]. As indicated in
Figure 10, the alpha and beta chains of integrin molecules act as
receptors for extracellular matrix and cell-surface ligands [44,45].
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Figure 8. A model of the biological activities of epidermal cell-derived
cytokines. Following a variety of exogenous stimuli (e.g., ultraviolet
irradiation) and endogenous stimuli, and, to a lesser extent, even
constituitively, keratinocytes produce a variety of cytokines (e.g., IL-1, contra-
IL-1, IL-3, GM-CSF, IL-6, TGF-alpha and TGF-beta, Basic FGF) which
influence differentiation, growth and function of many hematopoietic and
non-hematopoietic cells. Reproduced with permission from Stingl et al [30].
Figure 9. Schematic representation of the structure of some of the major
members of the Immunoglobulin Supergene Family. The cell membranes
are indicated by bilaminar structures and the transmembrane segments
and domains are noted for each protein. The lower panel represents
a T lymphocyte and the upper panel other cells. TCR¼T cell receptor;
CD¼Common Designation antigens; FcR¼ Fc Receptor for
immunoglobulins; CEA¼Carcinoembryonic antigen; PDGFR¼ Platelet-
derived Growth Factor Receptor; CSF1R¼Colony Stimulating Factor 1
Receptor; N-CAM¼Neuronal Cellular Adhesion Molecule. Adapted from
Williams AF: Immunology Today, 8:298–303, 1987 [38].
It appears that these types of receptor-ligand binding are crucial for many
interactions of leukocytes with either ECM or other cells [44–48].
The three major integrin families are described in detail in Table V. The
first two families mediate cell/matrix attachment. The third family, the
CD11/CD18 Family, is crucial to cell/cell interactions involving all
leukocytes and also the interaction of leukocytes with parenchymal cells.
The interaction of the receptor LFA-1 with its ligand ICAM-1 [46] appears
to be central to many cell-cell contact mediated processes, such as T and B
cell activation, lymphocyte cytotoxicity, and cell migration [47–50].
Families deficient in antigens ofthe CD11/18 Family exhibit a wide variety
of abnormalities in immunologic and inflammatory responses [49,50].
During 1988, it became apparent that modulation of ICAM-1 expression
may be a crucial component of control of inflammation. Although gamma
interferon and IL-1 upregulate the constituitive levels of ICAM-1 on
endothelial cells and fibroblasts [51], gamma interferon and perhaps tumor
necrosis factor (TNF) induce ICAM-1 expression of keratinocytes [52].
ICAM-1 expression on keratinocytes mediates LFA-1 dependent T
lymphoblast attachment to the keratinocytes, as elegantly demonstrated by
Dustin and collaborators [52]. This ICAM-l/LFA-1 interaction may be
involved in movement of T lymphocytes into the epidermis [53] and appears
to be essential for at least some forms of keratinocyte cytotoxicity [54]. The
role of adhesion molecules in epidermal cytotoxicity [31], and the induction
of ICAM-1 in cutaneous disease are both areas of active investigation.
Keratins. The study of differentiation of the epidermal keratinocyte is a
fundamental component of cutaneous biology. Advances in cell culture
and development of techniques in molecular and cellular biology have
attracted many scientists of disparate backgrounds to the study of the
maturation of keratinocyte proteins such as the keratins, involucrin,
filaggrin and keratolinin. The goal is to link structure and function,
through study of the ultrastructure, biochemistry and molecular biology
of keratinocyte differentiation. Studies of epidermal differentiation
pathways will lead to better understanding of the molecular basis for
the epidermal structure critical in stratum corneum organization, barrier
function, and permeability to drugs, toxins and allergens. Probes for
epidermal keratins are also important tools for studying epidermal
differentiation and malignant transformation in both experimental and
clinical settings.
Epidermal keratins comprise only two of the five types of intermediate
filaments which are important cytoskeletal components. As summarized
in Table VI, acidic keratins (Type I), neutral-basic keratins (Type II),
vimentin, desmin, glial fibrillary acidic proteins, neurofilaments and
lamins (universal components of nuclear lamina) are packaged in
aggregates to form the intermediate filaments [55]. In all epithelial
tissues, Type I and Type II keratins are associated with different patterns
at particular stages or pathways of differentiation. The origin and
differentiation of a particular cell type can be determined by identifying
the type of intermediate filament in its cytoskeleton using standard
monoclonal antibody probes.
The intermediate filaments are homologous in structure. As shown in
Figure 11, all types of intermediate filaments contain a highly conserved
central rod domain and variable N-terminal and C-terminal segments
comprising multiple domains. It is likely that these variable domains
determine the variable patterns of aggregation of the different inter-
mediate filaments. The association of Type I and Type II keratin, and
multiples of this pattern comprise keratin intermediate filaments [55].
Elegant contemporary studies of the role of different domains of the
cytokeratins in determining the pattern of aggregate or complex
formation represent the ‘‘state of the art’’ in molecular biology [56].
The molecular biology and molecular genetics of the cytokeratins has
been a particularly fertile area of research in developmental biology. In
fact, in 1987 an entire issue of Current Topics in Developmental Biology
was devoted to ‘‘The Molecular and Developmental Biology of the
Keratins’’ [57]. Extensive recent investigation has characterized the
human keratin genes and their expression [58], and the expression and
modification of keratins during terminal differentiation of the epidermis
[59]. Keratins are particularly popular with molecular biologists because
Figure 10. A schematic representation of the involvement of Integrins in
Cell-Cell and Cell-Matrix interactions. The Alpha and Beta subunits of
different integrins on leukocyte surfaces modulate interaction with matrix
and other cells by recognition of specific ligands: Fibronectin, vitronectin
and collagen for integrins ofthe first two subfamilies and either ICAM-1 or
C3bi for integrins ofthe third family (See Table V).
Table V. Integrin Superfamily
Three Major Conserved subgroups
Receptor Distribution Ligand
Alpha Beta
1. ‘‘Very Late Antigen’’ (VLA) Family
VLA1 210-kD 130 kD aTl ?
VLA2 165 130 kD aTl, pl Co
VLA3 135/25 130 kD cl, bm La, Co, Fn
VLA4 150 130 kD ly, mo ?
VLA5 135/25
a 130 kD pl, mo Fn
2. Vitronectin Receptor Family
Vitronectin receptor Vn
gp IIb/IIIa (CDw40) pl, IRC Fn, Vn, Fi, VWF
3. CD11/CD18 Family
LFA-1 190-kD (CD 11a) 95-kD (CD18) leu ICAM-1
MAC-1b 160-kD (CD 11b) (CD 18) mo, gr C3bi
gpl50,95 150-kD (CD 11c) (CD18) mo, gr C3bi
Legend: aTl=activated T lymphocytes, ly=lymphocytes, pl=platelets,
leu=all leukocytes, mo=monocytes/macrophages, gr=granulocytes,
cl=cell lines, bm=basement membrane, IRC=interdigitating reticular cells.
Fn=fibronectin, Vn=vitronectin, Co=collagen, VWF=Von Willebrand
Factor, La=laminin, Fi=fibrinogen, ICAM-1=Intercellular adhesion mole-
cule-1, C3bi=subunit of C3.
aFibronectin receptor.
bCR3 complement receptor.
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they are convenient markers for differentiation in all vertebrates [60], and
different patterns of keratin expression can be used to define distinct
pathways of epithelial differentiation. The developmental expression of
keratins and associated molecules, such as filaggrin, are important
markers of different stages of development as well as indicators of
specific cell and tissue function [61].
The study of expression of keratins is an important tool in the
study of carcinogenesis. Not only can keratins be used in models of
malignancy as markers of neoplasms with a stratified squamous origin
[62], but also keratins can be used to study sequentially the development
of malignancy and the environmental induction of malignant change
[63,64]. In 1988, regulation of keratin gene transcription was used
to evaluate malignant change [65]. Aside from applications in the
laboratory, probes for cytokeratins are being effectively applied by the
experimental pathologist to better characterize carcinomas as to stage of
differentiation [66,67]. The keratin patterns in different epithelial structures
are useful in identifying particular stages or pathways of differentiation in
cell or organ culture [68], and control of keratin expression is central to
understanding how different epithelial structures develop.
The preceding section has focused on the biology of six major groups
of proteins which are involved in different aspects of cutaneous structure
and function. The increasing functional interactions among these groups
of proteins certainly accentuate the complex and interactive aspects of
biology. Study of these proteins at the molecular, cellular, organ and
systemic levels has led to increasingly sophisticated understanding of
normal biology and disease. In the next section, we will consider how
such basic research relates practically to the diagnosis and treatment of
skin disease.
THE INFLUENCE OF RESEARCH IN CUTANEOUS
BIOLOGY ON THE PRACTICE OF DERMATOLOGY
This commemorative issue of the JID is filled with evidence of how basic
research in cutaneous biology is related to practical understanding of
disease mechanisms, and to understanding of how specific treatments are
effective in different diseases. In this section we will consider in more
detail how current research regarding the pathomechanisms of important
skin diseases leads to better methods of diagnosis and treatment.
Major Immunologic Diseases
Bullous Disorders. In no area of clinical dermatology has modern
research produced a greater impact on the accurate diagnosis and
treatment of disease than in the major bullous disorders. The major forms
of pemphigus, bullous pemphigoid, dermatitis herpetiformis, herpes
gestationis, acquired epidermolysis bullosa, and linear IgA dermatosis
can be separated based on distinctive immunohistologic findings. How
these immunoreactants produce clinical blister formation has been the
subject of extensive research, and the selection of anti-inflammatory and
immunosuppressive treatment for these diseases has been influenced by
the results of these investigations. The details of these reports are clearly
presented in this volume in the review by Stingl and Krueger and in the
‘‘Citation Classic’’ by Lee.
Connective Tissue Diseases. (Lupus erythematosus) Better under-
standing of the clinical subsets of lupus erythematosus and of the role of
lutoantibodies and ultraviolet light in the induction of cutaneous lesions has
been an important aim of research in investigative dermatology for a
number of years. Direct linkage of autoantibodies to mechanisms of tissue
damage in cutaneous lupus has been much more difficult than in the major
bullous disorders. Granular deposits of immunoreactants at the dermal-
epidermal junction in SLE and DLE lesions (the lupus band test, LBT) were
believed to imply a link between autoantibody and lesion development
[69,70]. However, extensive studies of the use of the LBT to predict
systemic disease in SLE patients have been variably convincing [71,72].
Recent research in cutaneous lupus has focused on the photosensitive
lupus syndromes subacute cutaneous lupus erythematosus (SCLE) and
neonatal lupus erythematosus (NLE). The strong association of these
syndromes with antibodies to the extractable nuclear antigens SS-A/Ro
and SS-B/La [73,74] has led to a series of investigations attempting to
link these autoantibodies to the tissue damage seen in photosensitive
lupus lesions. Binding of anti-SS-A/Ro antibodies to human keratinocytes
has been shown to occur both in vitro and in vivo [75,76], and is
augmented by UVL and estradiol [75,77], two trigger factors of lupus.
The isotype profile of anti-SS-A/Ro antibodies in the sera of SCLE patients
[78] and in the tissue of SCLE lesions is similar, and can be reproduced in
model systems by injection of anti-SS-A/Ro into nude mice engrafted
with human skin [76,79]. There is growing evidence that these antibodies
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Table VI. Distribution of Intermediate Filament
Proteins
Origin Common Name
Sequence
Type Chains
Size
(kD)
All epithelia Acidic keratinsa I B15 40–60
All epithelia Neutral-basic
keratinsa
II B15 50–70
Mesenchymal cells Vimentin III 1 53
Myogenic cells Desmin III 1 52
Glial cells and
astrocytes
Glial fibrilliary
Acidic proteins III 1 51
Most neurons Neurofilaments IV X4 for
vertebrates
57–150
Nuclear lamina
of all eukaryocytes
Lamins V X4 for
vertebrates
60–70
aAlso called cytokeratins.
Adapted from Steinert PM and Roop DR, Molecular and Cellular Biology
of Intermediate Filaments, in Annual Review of Biochemistry 57:593–625,
1988.
Figure 11. Summary of the homologous structure of the five major types of
intermediate filaments. The rod domains of the major intermediate filament
types are divided into two main segments, separated by globular linking (L)
regions. The different domains of the amino (N) and carboxy (C)-terminal
domains probably determine the patterns of association and interaction of
the different types of filaments. Adapted from Steinert and Roop [55].
are involved in producing tissue damage. Also, current investigations
into the immunogenetics of anti-SS-A/Ro antibody production [80] are
directed at determining the alleles which determine antibody production
and/or disease.
Treatment of cutaneous lupus erythematosus has benefited from the
development of effective topical steroids, the use of antimetabolites and
anti-inflammatory drugs in SLE, the use of antimalarials, the development
of broad-spectrum sunscreens, and more recently the development of
retinoids [81].
Scleroderma. In spite of extensive and productive study of the complex
cellular interactions involved in the production of fibrosis of multiple
organs in scleroderma, no effective treatment has been developed. Many
factors are involved in the genesis of scleroderma. Immunologic
reactivity seems to be central in natural scleroderma and in graft-
versus-host disease animal models of scleroderma [82]. Growth-factor
stimulation of fibroblast synthesis of collagen is central to the production
of fibrosis [83–85]. As previously discussed in this issue, growth factor
synthesis is associated in scleroderma tissue with perivascular infiltrates
[14]. Mast cell degranulation also appears to be involved in some
scleroderma models [86]. Detailed understanding of the factors which
control immunologic and growth factor-dependent fibrosis [87] are most
likely to lead to clinically relevant treatments.
Dermatitis
Contact Hypersensitivity. Investigative dermatologists and immunol-
ogists have focused on understanding the mechanisms of contact
hypersensitivity and allergic contact dermatitis for many years, producing
an impressive record of accomplishment. We understand in great detail
complex cellular interactions involved in contact hypersensitivity, now
even at the molecular level. These events are described in detail in the
review by Stingl and Krueger, in the ‘‘Citation Classic’’ by Soter, and in
previous sections of this chapter on immunologic cytokines and adhesion
molecules.
Detailed study of the antigens or sensitizers which induce allergic
contact dermatitis has also been a major focus of research in basic
research laboratories, in clinical departments and in the laboratories of
the pharmaceutical industry. The fact that the most cited paper from the
JID concerns the Maximization Test [88] to identify contact sensitizers
underlines the activity of research to understand the mechanisms of
sensitization and to identify real or potential sensitizers. In clinical
practice this has been translated into accurate patch testing and effective
identification and elimination of sensitizers. The development of potent
topical and oral steroids has made treatment quite satisfactory.
Photoimmunology has developed as an outgrowth of research in
mechanisms of contact hypersensitivity. Ultraviolet radiation is an
important immunomodulator affecting many aspects of cutaneous
immunology and inflammation [89]. This detailed understanding of
mechanisms of immunosuppression helps us to understand the impress-
ive effects of UVL in treating many skin diseases.
Photoallergy is based on many of the same mechanisms as contact
hypersensitivity. The detailed study of mechanisms of photoallergy and
phototoxicity has important clinical application in evaluating light-
induced drug reactions and photo-related reactions to topical chemicals.
The epidemic of persistent light reactions was controlled by identifying
the photosensitizers involved, and by carefully screening future
compounds as photosensitizers.
Atopic Dermatitis. Not all cutaneous conditions have yielded to the
tools of modern investigation. One of the most common skin conditions,
atopic dermatitis, continues to frustrate current investigators, just as it did
their predecessors. Yet small pieces of the atopic dermatitis puzzle
tantalize us with the promise of a major scientific breakthrough.
Studies of the pathology of atopic dermatitis began in the Journal and
continue to serve as the basis for current investigation [90,91]. The
observed prominence of the cutaneous mast cell and the Langerhans
cells in these studies provides the impetus for involvement of the immune
system in atopic dermatitis [91,92]. The observation of elevated skin
histamine levels was first reported in the Journal [93].
The contradictory findings of an inflammatory disease which has
evidence of cellular immunodeficiency, altered pharmacologic reac-
tions, paradoxical vascular responses, abnormal sensory nerve responses,
and a defective epidermal barrier have been difficult to encompass with a
unifying concept. Jon Hanifin, Kevin Cooper and their colleagues have
focused on second messenger cellular systems in hopes of detecting a
common defect in the recognition of cellular modulatory signals, and
their concept of altered signal transduction by a receptor-mediated cAMP
second messenger has been partially substantiated by recent investiga-
tions [94]. The cellular immunodeficiency of atopic dermatitis has also
been well documented by a large number of careful investigations [95].
The complexity of atopic dermatitis has been appreciated as more
abnormal responses and interactions are catalogued [96].
Despite large gaps in our understanding of atopic dermatitis, scientific
advances in pharmacology have greatly improved our therapy. We now
employ elegant topical glucocorticosteroid preparations which provide
prompt relief, instead of messy tars which stink and stain; we now utilize
specific anti-staphylococcal antibiotics, whereas previously atopic
dermatitis patients suffered daily from chronic cutaneous infection; we
can provide antihistamines and other antipruritics to relieve the
intractable itching, and we have a selection of phototherapy protocols
to offer.
The Journal has published a large number of studies on atopic
dermatitis in the past half century, and many others have appeared in
other prominent journals with the frustration that, although a large
volume of data have been accumulated regarding atopic dermatitis, we
are currently not very close to understanding the disease. It may be the
fact of cutaneous biology that atopic dermatitis is a disease for the
twenty-first century to master.
Psoriasis. Investigative studies of psoriasis continue to produce evidence
of abnormalitis in epidermal proliferation, epidermal differentiation, and
inflammation in psoriatic skin, but it is rarely clear whether the defects
demonstrated are the cause, or the result, of the disease. Perhaps, the
host-specific abnormality that leads to psoriasis is not a single defect;
there may be a number of abnormalities which singly, or in combination,
lead to.psoriasis. In addition, there also may be a number of
environmental stimuli which are critical determinants in the genesis of
psoriasis.
Recent studies of psoriasis have documented further the abnormal
proliferation and differentiation characteristic of psoriatic epidermis
[97–99]. Other findings that may be related to these abnormalities
include defects in signal transduction in cell membranes [100–102],
increased polyamine synthesis and ornithine decarboxylase activity
[103,104], and increased binding of epidermal growth factor [105].
Products derived from proteases and from enzymes that metabolize
eicosanoids may also lead to proliferative and differentiation abnormal-
ities, as well as to the influx of inflammatory cells [106–108]. Powerful
chemattractants, such as leukotriene B4, appear to be important factors in
the neutrophilic inflammation characteristic of psoriasis [108]. Further
investigations have shown endothelial cell abnormalities and increased
adhesion of lymphocytes to psoriatic endothelium [109,110].
Considerable attention has been focused recently on a hypothesis that
the immune system and interactions of cells of the immune system with
cells of the skin leads to psoriasis (see Figure 12) [110]. The presence in
active psoriatic lesions of increased numbers of epidermal T-lympho-
cytes, of HLA-DR positive cells, and of Langerhans cells are observations
that support this hypothesis [111,112]. Active psoriatic lesions have been
observed to have a larger proportion of helper T lymphocytes, while
resolving lesions contain more suppressor T lymphocytes.
Investigative efforts have provided a number of novel therapies for
psoriasis. Therapy of psoriasis with PUVA and with retinoids (see the
‘‘citation classic’’ by Bernhard and the review by Saurat) may affect both
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of the proliferative-differentiation abnormalities and the inflammatory
processes. A recent fascinating therapeutic observation is that the
immunosuppressive drug cyclosporin A may be of benefit in psoriasis
[113]. This unique drug may work through its effects on the immune
system, or it may have a direct effect upon keratinocyte proliferation
[114,115]. Attention to how this drug and other therapies work in
psoriasis may provide valuable clues to the pathogenesis of this important
dermatologic disease.
Lichenoid Dermatitis. Lichen planus and histologically similar
lichenoid eruptions are an interesting and important form of papulo-
squamous dermatitis which has been extensively studied by histologic
and immunohistologic techniques. Still, little is known about the
immunologic mechanisms of these cutaneous reaction patterns. A series
of papers has provided new insights into possible mechanisms for the
dense dermal infiltrate and keratinocyte damage seen in lichenoid
dermatitis [116,117]. In a mouse model of lichenoid tissue reactions
produced by injection of autoreactive T-cell clones, Shiohara and his
colleagues have found that different clones produce distinct patterns of
tissue reactivity. Some clones produce a dense mononuclear infiltrate
and keratinocyte hydropic change as in lichen planus [Fig 13]. This
model is being used to study the factors involved in epidermotropism
[117] of lymphocytes and keratinocyte cytotoxicity and may produce
practical therapeutic approaches to epidermotropic dermatitis and
malignancy.
Fibrotic Skin Diseases
The factors involved in immunologic fibrosis have already been
discussed in relation to scleroderma. The review by Uitto, Olsen and
Fazio clearly describes the great progress made in the study of primary
diseases of altered collagen and elastin synthesis and deposition, plus
understanding of changes which occur with aging and UV radiation. Of
central importance in modern research of these diseases is understanding
that the altered regulation of collagen synthesis can occur at the
pretranslational level [118]. This is reflected in two current JID papers.
Olsen et al. illustrate that elevated ECM synthesis in lipoid proteinosis
may be caused by elevated mRNA for procollagen [119] in patients’
dermal fibroblasts grown in vitro. Sephel et al. show that increased
elastin production by progeria skin fibroblasts is controlled by elevated
steady-state levels of elastin mRNA [120]. Better understanding of the
molecular basis for altered synthesis of connective tissue components
may lead to better clues to practical ways to regulate the process and
produce normal connective tissue in patients with this group of diseases.
Acne Vulgaris
One of the true ‘‘success stories’’ of investigative dermatology is the study
of the pathogenesis and treatment of acne vulgaris. The pathogenesis of
this complex cutaneous inflammatory disease has been well character-
ized, and effective treatments reversing the major components of the
pathomechanism have been developed. In 1988, the use of combination
therapy and the effective use of modern retinoids have made it possible
to control even the most severe recalcitrant cystic acne.
The decade of the 1970s was a golden age in acne research, during
which time the major components of the pathogenesis of this disease
were identified. The JID was a major source for landmark papers of that
era, and the state of understanding of research in sebaceous gland
physiology and its relationship to acne at that time was well presented in
a review by Kligman [121]. The development of acne is based on five
major components: follicular hyperkeratosis; enhanced sebaceous
activity; overgrowth of Proprionobacterium acnes (historically, Coryne-
bacterium acnes); generation of chemotactic substances; and recruitment
of a neutrophilic infiltrate which produces tissue damage and scarring.
Follicular retention hyperkeratosis is a uniform characteristic of sebaceous
follicles in acne patients, and appears to be the necessary factory for
the development of the co-medone, the primary lesion of acne [122,123].
The composition of sebum in acne patients appears to be able to
induce acne lesions in animal models [124] and to influence acne by
directly stimulating follicular hyperkeratosis [125] and promoting growth of
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Figure 12. An in vitro cell attachment assay using psoriatic skin as substrate.
This figure shows binding of rat thoracic duct lymphocytes to the papillary
dermis of psoriatic skin. Minimal binding was seen in the epidermis, in the
reticular dermis, or in normal skin. From Sackstein et al., J Invest Dermatol,
91:423–428, 1988 [110].
Figure 13. Lichenoid Tissue Reaction (LTR) produced in B6 nude mouse
footpad after injection of autoreactive T cell clones. Note the epidermotropic
infiltrate and hydropic epidermal change. From Shiohara et al. J Invest
Dermatol 91:69–75, 1988 [117].
P. acnes. The bacterium P. acnes appears to be necessary for the
development of the retention hyperkeratosis which produces comedonal
lesions, and also for the production of inflammatory lesions [126–128].
Inflammation is produced by direct effects of products of P. acnes on the
follicular epithelium [129], by production of irritating free-fatty acids from
sebum [130,131], and by the generation of chemotaxins [132]. The
neutrophilic infiltrate which ensues produces local erythema and often
severe scarring and sometimes epidermal atrophy.
Hormonal influences in the development of acne have been well
documentated [133–136]. Not only do systemic androgen levels
influence sebaceous gland activities and acne development [133–135],
but cutaneous androgen metabolism may also be a critical part of the
genesis of acne lesions [136]. The importance of this work in
investigative dermatology can be judged by the fact that four of these
papers are in the top 200 most-cited papers in the JID [133,134,136,137].
The use of oral and topical antibiotics, benzoyl peroxide and topical
retinoic acid reverses these pathogenic changes in acne patients and
controls most patients. For recalcitrant patients or those with particularly
severe acne, the introduction of 13-cis-retinoic acid was an important
development [138]. This drug reverses retention hyperkeratosis, de-
creases sebum production, inhibits P. acnes growth, and strongly inhibits
the inflammatory reaction in the skin [139].
Contemporary research in acne and sebaceous gland function is
utilizing modern methods of cell culture and accurate probes for
differentiation proteins to grow sebaceous follicular cells in culture and
study their differentiation patterns in acne lesions [140] and in cell
cultures exposed to the inciting agents of acne.
Photobiology
The review by Bickers earlier in this volume succinctly presents the impact
of some of the major discoveries in photobiology over the past 50 years as
reported in the Journal of Investigative Dermatology. The mechanisms of
ultraviolet light as an agent of photoallergy and phototoxicity, as the cause
of photoaging, in photocarcinogenesis, and in induction of photosensitive
disease have been productively studied. This knowledge has been applied
to ways to avoid ultraviolet light induced disease: to screening to remove
photosensitizers from topical medications and toiletries, and to the
development of potent sunscreens, in itself a major development in
medicine. In addition, the therapeutic effects of ultraviolet radiation are
now much better understood through studies in photoimmunology.
Certainly one of the most dramatic effects of photobiology in the
practice of dermatology has been the development of PUVA and its
application to the treatment of many skin diseases. This story is presented
with sparkling clarity by Jeffrey Bernhard in his ‘‘Citation Classic’’
commentary.
There is incredible public interest in the mechanisms of photoaging
and in ways to reverse the changes. Two contemporary studies from the
University of Pennsylvania investigate the degradation of elastin fibers by
UVL [141] and the ultrastructural features of chronic heliodermati-
tis.[142] Chronic sun-damaged skin contains a lymphohistiocitic
infiltrate with prominent mast cells in association with fibroblasts.
Perhaps the concepts discussed earlier with respect to scleroderma also
apply to chronic sun-damaged skin.
Pigmentary Disorders
The review by Nordlund et al. on the historical development of
melanocyte biology indicates the importance of the melanocyte in
cutaneous biology and the importance of disorders of pigmentation and
melanoma in medicine. The development of techniques for the culture of
melanocytes has greatly advanced attempts to understand the cell
biology of melanocytes and the control of melanization. There is
especially great interest in identifying the biologically relevant factors
which influence melanocyte proliferation and migration and melaniza-
tion in vivo. An example is the current efforts to determine whether
vitamin D and its metabolites directly influence melanization. Mason
et al. [143] tested the effects of vitamin D and its metabolites on
melanocyte cell lines, and found that all cell lines bound 1,25(OH)2D3;
and evidenced increased tyrosinase activity in response to active vitamin
D. Calcitonin effects on these cell lines was variable. Tomita et al. [144]
found that cholecalciferol (Vitamin D3) enhanced immunoreactive
tyrosinase activity in cultured human melanocytes, speculating that the
photoactivation of vitamin D3 from provitamin D3 may be a direct
mediator of UVL-induced melanization. However, Mansur et al. did not
find that active vitamin D3 (or its precursors, or its metabolites)
stimulated melanogenesis in cultured human melanocytes [145], raising
questions about the true role of vitamin D in pigmentation.
Culture of human melanocytes has also facilitated the study of
pigmentary disorders associated with inflammatory reactions. Vitiligo is a
complex process which is found in man and many animal models, and
there is considerable indirect evidence that one of the basic mechanism
is autoimmune destruction of melanocytes. A functional role for
antimelanocytes antibodies in vitiligo was verified by two different
antibody dependent immunologic mechanisms [146], which employed
normal melanocytes in culture as sensitive targets of immunologic
cytotoxicity. In addition, melanocytes in culture showed greater
susceptibility than cultured keratinocytes, fibroblasts and endothelial
cells to lysis by hydrogen peroxide, a mediator produced in many types
of inflammatory reactions [147]. This susceptibility to toxic oxygen
products may be interpreted as a possible mechanism for the melanocyte
dysfunction evident in post-inflammatory hypopigmentation. Advances
in cell culture techniques have made possible the detailed study of
melanocyte function in normal and pathologic circumstances.
Much interest in clinical studies has centered on ways to encourage
repigmentation of depigmented lesions of vitiligo. Application of modern
knowledge of cell movement, matrix proteins and growth factors may
provide the key to stimulation melanocyte repopulation of depigmented skin.
Wound Care
Wound Healing. Practical approaches to care of nonhealing wounds is
an important result of the extensive studies on wound healing.
Modern semipermeable dressings and modern disinfectants and
antibacterial ointments have been developed based on basic research
on the factors influencing wound healing. A whole new chapter on
promotion of wound healing is opening, with clinical trials using
recombinant growth factors on non-healing ulcers in humans.
Artificial Skin (Skin Equivalents). An emerging practical application
derived from basic research in immunology and cell biology is the use of
allogeneic dermis, or an artificially constituted dermal equivalent, and
cultured autologous keratinocytes to produce a ‘‘skin equivalent’’ suitable
for grafting onto burns, surgical defects, or ulcers of the skin. The
epidermis, with its Langerhans cells, appears to be the most immunogenic
component of skin allografts, but recently available keratinocyte culture
techniques have provided a convenient means by which epidermal cells of
a potential graft recipient can be harvested and expanded in numbers and
then used to produce an epidermal autograft [148–150]. Regardless of
which technique is used to produce a dermis, the connective tissue is
eventually colonized by cells of recipient origin [151–154]. By providing
cultured autologous keratinocytes to cover the underlying fibrovascular
stroma, these techniques allow more rapid coverage of large defects than
would occur as a result of migration of cells from the wound edges. The
stratified epithelium that is eventually produced at the graft sites with these
methods appears to be relatively normal in both its structure and function,
although the appearance may not be optimal [149–153], As these practical
applications of recent investigative dermatology improve, perhaps we will
have effective, life-saving methods of covering burns and other cutaneous
defects with the equivalent of skin autografts.
Prenatal Diagnosis
Prenatal diagnosis of skin diseases became a reality in the 1980s, as a
direct result of scientific technology developed in the preceding decade.
Over 150 distinct genetic skin diseases have been detected in man, many
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of which result in chronic suffering for the affected individuals. Thus, the
interest in prenatal diagnosis of skin diseases has been keen. For the
families with a history of a devastating genetic skin disease, there was no
prenatal diagnosis prior to this decade.
Modern obstetrics and perinatal medicine first developed ultrasono-
graphy, which was useful in the prenatal diagnosis of major malforma-
tions, then mid-trimester amniocentesis for biochemical measurements of
amniotic fluid. Skin diseases were not amenable to such strategies, and it
requied the development of fetoscopy and fetal skin biopsy to enable one
to diagnose skin diseases prenatally.
The pioneering work of Karen Holbrook and George Odland in 1980
opened the door for the prenatal diagnosis of skin diseases by carefully
documenting the normal ultrastructure and morphology of the first-
trimester embryo and the second-trimester fetus [155]. Shortly after,
Sherman Elias and Nancy Esterly reported the prenatal diagnosis of
harlequin ichthyosis [156]. Prenatal diagnosis of the genetic mechan-
obullous diseases followed. Robin Eady and colleagues described the
prenatal diagnosis of junctional epidermolysis bullosa, and Ingrid Anton-
Lamprecht, of recessive dystrophic epidermolysis bullosa [157,158].
Oculocutaneous albinism was the next to be diagnosed prenatally with a
report from Robin Eady in the Journal [159].
In addition to ultrastructural analysis of fetal skin samples, prenatal
diagnosis of skin disease has also been successful after biochemical analysis
of skin cells cultured from fetal skin biopsies. Eugene Bauer and his
colleagues were able to diagnose recessive dystrophic epidermolysis bullosa
with biochemical studies of collagenase from cultured fetal fibroblasts [160].
Since ultrastructural analysis was not widely available, Heagarty and
Eady applied immunofluorescent techniques to fetal skin samples for the
rapid prenatal diagnosis of epidermolysis bullosa [161]. This advance
was made possible by the development of monoclonal antibodies to the
structural components of the dermal-epidermal junction, and the first
description of this technique by Hintner and colleagues in 1981, which
allowed diagnosis of the major types of epidermolysis bullosa [162].
Despite the reports of prenatal diagnoses in the ichthyoses and
mechanobullous diseases, limitations of the current technologies have
recently been detailed [163]; and the majority of genetic skin diseases
cannot be diagnosed in the prenatal period. Somehow, the feeling
prevails that the best is yet to come for prenatal diagnosis of skin diseases.
With the powerful sensitivity and specificity of molecular biology
techniques, detection of abnormal genes encoding for genetic skin
disorders holds great promise for prenatal diagnosis in the decade ahead.
Dermatopathology
The contributions of basic research have revolutionized the practice of
skin pathology in the past 15 years. Immunofluorescence microscopy has
enabled the skin pathologist to distinguish the major bullous diseases (see
review by Stingl and Krueger). Immunophenotyping of cutaneous
infiltrates began as an investigative tool in the 1970s, as demonstrated
by two early landmark papers by Edelson and Thivolet [164,165], and
has grown in application to become a broadly used tool in clinical and
pathologic research and a clinical diagnostic tool. The development of
monoclonal antibodies and superior labeling and fixation techniques has
greatly expanded the diagnostic repertoire of the skin pathologist [166].
Immunoperoxidase or immunogold labeling of the surface of cells
infiltrating the skin enable the pathologist to distinguish malignant from
benign lymphohistiocytic infiltrates [167]. This has been particularly
helpful in the diagnosis of cutaneous T cell lymphoma by detection of the
CD4 reactive epidermal lymphocytes [168], and in distinguishing benign
from malignant histiocytosis [169].
In some circumstances the early promise of such immunodiagnostic
techniques has not resulted in improved diagnosis in skin pathology. This
has been particularly true of the innumerable immunophenotyping
studies of benign inflammatory skin diseases [167]. It is now apparent
that the wide variety of inflammatory skin diseases demonstrate quite
restricted patterns of infiltrating leukocytes, mimicking patterns seen in
other tissues.
Immunoperoxidase techniques have been invaluable to the skin
pathologist in distinguishing some forms of cutaneous malignancies. For
example, the spindle tumors demonstrate such overlapping morphology
that they are often impossible to distinguish by routine histopathology. The
modern skin pathologist with a panel of highly specific or even mono-
clonal immunologic reagents is now able to make a specific diagnosis.
Atypical fibroxanthomas, for example, react with antibodies to vimentin,
alpha-1 antitrypsin, and alpha-1 antichymotrypsin, while squamous cell
carcinomas react with panels of antikeratin antibodies; malignant
melanoma reacts with S-100 and monoclonal antimelanoma antibodies;
and leiomyosarcomas react with anti-desmin antibodies [170].
The experimental pathologist has applied such immunoreagents to
discover the spirochete which is the causative agent of Lyme disease
[171], to detect human papillomaviruses in a variety of epithelial growths
[172], and to find herpes simplex virus antigens in skin lesions of
erythema multiforme [173].
The dermatopathologist of the next decade must adapt to the ever
improving panels of diagnostic reagents, including not just monoclonal
antibody probes, but also molecular and nucleotide probes which will
become the diagnostic reagents that will further sophisticate and refine
the field of skin pathology.
Carcinogenesis
The review in this issue by Bickers and Lowy provides an excellent
perspective on the development of the major theories of carcinogenesis,
and a sampling of important papers in the development of modern
models of carcinogenesis. The JID continues as an important forum for
publication of papers in ultraviolet and chemical carcinogenesis, and for
papers concerning viral carcinogenesis.
A high priority in investigative dermatology is the development of
probes for human papillomaviruses to diagnose particular papilloma
presentations that are associated with subsequent development of cancer
[174]. The role of interferons and other biologic response modifiers in the
treatment of papilloma virus-associated skin lesions is also an important
area of research [175].
One increasingly important area of research in viral oncogenesis is
the area of retrovirus infection. Not only is the skin commonly involved
with a variety of infections and Kaposi’s sarcoma in AIDS patients, but
the human immunodeficiency virus is found in epidermal Langerhans
cells [176]. A recent clinically oriented symposium of the ESDR focused
on the problem of AIDS, considering the biology of the disease, and new
clinical approaches [177]. The editors hope to have the opportunity to
review more work on the cutaneous role in this important syndrome.
Percutaneous Absorption
The structural, biophysical and biochemical factors which influence
percutaneous absorption, transepidermal water loss, and the epidermal
barrier are all reported in the JID, and are recognized by the Editorial
Board as one very important area in which basic research produces
practical benefits. The differentiation of epidermis and development of an
intact stratum corneum are considered in detail in the review by
Holbrook in this issue. Basic research in the role of intermediate
filaments, filaggrin, keratolinin and other proteins in formation of the
stratum corneum are a major basic scientific influence in investigative
dermatology. Detailed morphologic, biochemical and biophysical study
of the role of stratum corneum lipid and proteins in formation of the
epidermal barrier has produced an increasingly sophisticated knowledge
of the structure/function relationships in the stratum corneum, as
exemplified by several current JID papers [178–180]. This is an area of
research where basic science and practical application merge, and the
development of future transepidermal and transdermal delivery systems
is surely based on today’s research of the epidermal barrier.
New Approaches to Treatment
The scientific basis for new approaches in treatment of skin disease
frequently appear in the Journal of Investigative Dermatology. The review
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by Saurat on Clinical Research certainly illustrates this, and several
examples from 1988 confirm this point. One area of great professional and
lay interest is the use of retinoids to reverse the effects of photoaging in the
skin. A recent paper by Bryce in the Journal [181] illustrates some of the
relevant biological effects of topical retinoids in a hairless mouse model of
photoaging. These investigators demonstrated that topical tretinoin and
isotretinoin both reversed several characteristic findings in photoaging skin
in the mouse, and produced objective quantitative evidence of repair. As
illustrated in Figure 14, significant dermal repair was induced in irradiated
skin by topical retinoids. Such careful animal investigation provides the
basis for experimental and therapeutic protocols in humans to study further
the role of retinoids in the reversal of adverse effects of UVL.
There is also considerable clinical and investigative interest in the
control of hair growth and in the reversal of male pattern hair loss,
sparked by the authorization by the FDA for the use of topical minoxidil
for male pattern hair loss. Buhl and his colleagues [182] have examined
the growth characteristics of isolated hair follicles in organ culture and
the effects of minoxidil. Interestingly, they found that minoxidil added to
cultures stimulated follicular DNA and protein synthesis and incorpora-
tion of protein into hair matrix. Direct stimulation of follicular function
appears to be one of the potential mechanisms of action of minoxidil in
restoring hair growth.
Organ culture of isolated sebaceous glands was used by Sawaya et al.
[183] to study selected aspects of the metabolism of steroid hormones in
the skin. They found that even weak androgens could be metabolized to
more active androgens in sebaceous glands, and that such glands from
the scalp of bald men had increased activity. Thus, not only is the skin an
important site of generation of active androgens, but this activity is
greater in the scalp of balding men than in controls.
Photobiology has produced a number of important therapeutic
advances in recent years. The logical extension of the PUVA story is
the recent publication in the Journal of two contributions from the
members of the Photochemotherapy Follow-up Study [184,185],
documenting the actual five-to-ten-year risks of skin cancer and
cardiovascular disease, and cancer and cause of death in PUVA patients.
PUVA has also been shown to be an effective repigmenting treatment in
vitiligo, and other photoactive drugs, such as Khellin, have great promise
as improved repigmenting agents. As basis for clinical use, a recent paper
in the Journal documented the photo-therapeutic, photobiologic and
photosensitizing properties of khellin [186].
A direct result of the extensive research on PUVA and especially on
the immunosuppressive effects of PUVA is the development of
extracorporeal photochemotherapy for the treatment of cutaneous T cell
lymphomas (CTCL). This unique form of therapy involves separation of
leukocytes from patients in a special pheresis machine, extracorporeal
irradiation of psoralen-contaimng cells ‘with UVA, and reinfusion of the
irradiated cells back into the patient. Impressive success with recalcitrant
CTCL patients has been reported [187], and it is likely that this therapy
will be effective in other patients with diseases such as scleroderma and
rheumatoid arthritis, and in organ transplant patients [188].
The use of lasers in medicine is an excellent example of the application
of modern technology to practical clinical problems. Certainly one of the
most impressive examples of this is the treatment of port-wine stains with
the pulsed dye laser, which has been recently shown to produce excellent
clinical responses in children, as well as adults [189]. The use of this laser
is based on the selective absorption of the emitted light by hemoglobin in
hemangiomas and the minimal heat dispersal due to the pulse length and
spot size. A recent paper by Tan et al. [190] in the Journal documents some
of the histologic findings in resolution of port-wine stains following laser
treatment. A prominent role of mast cells in the neovascularization can
be inferred from the results (Fig 15). A number of other papers on the
biological effects of lasers [191,192] demonstrate the commitment of the
Figure 14. Histologic sections through UVB-irradiated hairless mouse skin.
The mouse in panel A is the control irradiated mouse and the mouse in panel
B received 100 mg 13-cis-retinoic acid topically three times weekly for ten
weeks. Greatly increased thickening of a ‘‘repair zone’’ in the papillary
dermis is seen, and epidermal thickening is also observed. From Bryce et al.,
J Invest Dermatol, 91:175–180, 1988.
Figure 15. Photomicrograph of a dermal vessel from a port-wine stain one
year after treatment with the pulsed dye laser (577 nm). The majority of
vessels were of normal caliber and lined with endothelium (E) that bulged
into the vessel lumens (L). Within the surrounding dermis (D), a normal
number of mast cells (M) exhibited cytoplasmic granules in various stages of
degranulation. From Tan OT et al., J Invest Dermatol, 90:395–398, 1988.
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JID Editorial Board to publish papers documenting the mechanisms of
action of new treatments or drugs.
CONCLUSION
As the finale to this special issue commemorating the founding of
the Society for Investigative Dermatology, Inc., and the Journal of
Investigative Dermatology, we have provided our own perspective on the
state of research in investigative dermatology in the 50th Anniversary
year, and have given examples of the impressive impact of basic research
on the practice of dermatology. If it is true that ‘‘the best of prophets of
the future is the past’’,* then what does the future hold for investigative
dermatology? Our prediction is for continued strong and productive
collaborations between basic and clinical investigators to discover the
unknowns in cutaneous biology, a continuation of the pattern that has
produced an impressive record of accomplishment over the past 50
years. We also predict that new and innovative treatments for skin
disease will be developed based on basic and clinical research, and will
often utilize the accessibility of the skin to irradiation and lasers, to
ultrasound and other physical modalities, and to the topical applications
of new drugs and biological response modifiers.
The techniques applied to cutaneous biology have become progres-
sively more elegant, and increasing numbers of scientists from academic
departments other than dermatology have found the skin to be a fertile
area of research. We must continue and even expand this application
of basic research to understanding and treating clinical disease. To
accomplish this and to assure that investigative dermatology survives as a
cohesive and comprehensive area of investigation, we must guarantee
that both the basic scientist and the clinical investigator feel represented
in the Journal and its sponsoring societies, the SID and ESDR. We are
committed to expanding the involvement of Ph.D. investigators in
all aspects of the Journal organization: as reviewers, as authors, and as
members of the Editorial Board. In this 50th Anniversary year, we
propose to expand the Editorial Board of the Journal to increase the
involvement of Ph.D. scientists, especially in the areas of molecular and
cellular biology.
The Founders of the SID and JID were committed to the concept of a
unified and inclusive approach to the study of cutaneous biology,
encompassing all aspects of modern science. To perpetuate this vision,
we must recruit actively the best scientists to study the biology of the skin
and to apply this knowledge to clinical dermatology. It is essential for the
continued success of the Journal of Investigative Dermatology that both
the basic and clinical investigator be involved in all aspects of the Journal
and its sponsoring societies, and that the newest technology be applied
intelligently to basic and clinical investigative problems. Such steps are
necessary for the Journal to continue to be considered as the best single
forum for the presentation of the entire spectrum of cutaneous biology.
We express our sincere appreciation to Beverly Polt, Editorial Assistant for The Journal of
Investigative Dermatology, for her dedication and competent assistance in preparing this special
commemorative issue of the JID. We also expresstmr appreciation to David Bickers, M.D., who
was chairman of the program committee that organized the 50th Anniversary’ Meeting of the
Society for Investigative Dermatology, for providing for this issue certain material from that
meeting and for his substantial contributions to this issue.
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